|
WO2009095478A1
(en)
|
2008-01-31 |
2009-08-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
|
FI4209510T3
(fi)
|
2008-12-09 |
2024-03-22 |
Hoffmann La Roche |
Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
KR102418979B1
(ko)
|
2012-05-15 |
2022-07-11 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
DK2904011T3
(en)
|
2012-10-02 |
2017-12-04 |
Bristol Myers Squibb Co |
COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATMENT OF CANCER
|
|
CA2894879A1
(en)
*
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
|
SG10201709290XA
(en)
*
|
2012-12-21 |
2018-01-30 |
Medimmune Llc |
Anti-H7cr Antibodies
|
|
US9657082B2
(en)
|
2013-01-31 |
2017-05-23 |
Thomas Jefferson University |
PD-L1 and PD-L2-based fusion proteins and uses thereof
|
|
RS56566B1
(sr)
|
2013-03-06 |
2018-02-28 |
Astrazeneca Ab |
Inhibitori hinazolina aktivirajućih mutantnih oblika receptora epidermalnog faktora rasta
|
|
KR20220053691A
(ko)
*
|
2013-03-15 |
2022-04-29 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
|
WO2014194293A1
(en)
*
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
US20160145355A1
(en)
*
|
2013-06-24 |
2016-05-26 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
HUE046964T2
(hu)
|
2013-08-08 |
2020-04-28 |
Cytune Pharma |
Kombinált gyógyászati készítmény
|
|
DK3444271T3
(da)
|
2013-08-08 |
2022-01-10 |
Cytune Pharma |
Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
CN105722992B
(zh)
|
2013-09-13 |
2021-04-20 |
豪夫迈·罗氏有限公司 |
用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法
|
|
HK1225988A1
(zh)
|
2013-09-13 |
2017-09-22 |
F. Hoffmann-La Roche Ag |
包含纯化的重组多肽的方法和组合物
|
|
ES2927567T3
(es)
*
|
2013-09-13 |
2022-11-08 |
Beigene Switzerland Gmbh |
Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
|
|
EA036902B1
(ru)
|
2013-09-20 |
2021-01-13 |
Бристол-Майерс Сквибб Компани |
Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
|
|
WO2015048312A1
(en)
*
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
LT3081576T
(lt)
|
2013-12-12 |
2019-10-25 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas
|
|
SI3466949T1
(sl)
|
2013-12-24 |
2021-03-31 |
Bristol-Myers Squibb Company |
Triciklična spojina kot sredstvo proti raku
|
|
AU2015205753A1
(en)
|
2014-01-10 |
2016-07-21 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for treating HER2 positive tumors
|
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CN106255510A
(zh)
|
2014-03-05 |
2016-12-21 |
百时美施贵宝公司 |
使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌
|
|
KR102248804B1
(ko)
|
2014-03-12 |
2021-05-11 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
EP3116909B1
(en)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
RU2695332C2
(ru)
|
2014-05-15 |
2019-07-23 |
Бристол-Маерс Сквибб Компани |
Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
|
|
JP6449338B2
(ja)
|
2014-06-06 |
2019-01-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
|
|
WO2015188085A1
(en)
|
2014-06-06 |
2015-12-10 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
CN110156892B
(zh)
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
AU2015286043B2
(en)
|
2014-07-09 |
2020-08-20 |
Birdie Biopharmaceuticals Inc. |
Anti-PD-L1 combinations for treating tumors
|
|
CA2954868C
(en)
|
2014-07-11 |
2023-08-29 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
|
EP3171892B1
(en)
|
2014-07-22 |
2021-11-24 |
Apollomics Inc. |
Anti-pd-1 antibodies
|
|
CN105330740B
(zh)
*
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
CN110964108B
(zh)
|
2014-08-05 |
2023-07-07 |
中美冠科生物技术（太仓）有限公司 |
抗pd-l1抗体
|
|
EP3177644B1
(en)
|
2014-08-05 |
2020-10-07 |
Mabquest SA |
Immunological reagents binding to pd-1
|
|
HRP20201153T1
(hr)
|
2014-08-08 |
2021-01-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Pd-1 sredstva visokog afiniteta i načini uporabe
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
AU2015314756A1
(en)
|
2014-09-13 |
2017-03-16 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
HUE051193T2
(hu)
|
2014-09-16 |
2021-03-01 |
Innate Pharma |
Gátlási reakcióút semlegesítése limfocitákban
|
|
US10766966B2
(en)
|
2014-10-10 |
2020-09-08 |
Innate Pharma |
CD73 blockade
|
|
JP6991857B2
(ja)
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
KR102589557B1
(ko)
|
2014-10-21 |
2023-10-16 |
시클론 파마수티컬 인터내셔널 리미티드 |
면역 자극인자를 이용한 암의 치료
|
|
CA2965495C
(en)
|
2014-10-23 |
2022-05-24 |
Regeneron Pharmaceuticals, Inc. |
Cho integration sites and uses thereof
|
|
EP3209778B1
(en)
|
2014-10-24 |
2019-04-03 |
Astrazeneca AB |
Combination
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
WO2016069727A1
(en)
|
2014-10-29 |
2016-05-06 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
WO2016067035A1
(en)
|
2014-10-29 |
2016-05-06 |
Bicycle Therapeutics Limited |
Bicyclic peptide ligands specific for mt1-mmp
|
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
|
WO2016073738A2
(en)
|
2014-11-05 |
2016-05-12 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
|
UY36391A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
|
|
SMT202000413T1
(it)
|
2014-11-21 |
2020-09-10 |
Bristol Myers Squibb Co |
Anticorpi nei confronti di cd73 e loro usi
|
|
MX386942B
(es)
|
2014-11-21 |
2025-03-19 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas.
|
|
EA201791049A1
(ru)
|
2014-12-04 |
2017-10-31 |
Бристол-Майерс Сквибб Компани |
Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
TW201630907A
(zh)
|
2014-12-22 |
2016-09-01 |
必治妥美雅史谷比公司 |
ＴＧＦβＲ拮抗劑
|
|
MA40662B1
(fr)
|
2014-12-23 |
2020-12-31 |
Bristol Myers Squibb Co |
Anticorps contre tigit
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
US9884868B2
(en)
|
2015-03-02 |
2018-02-06 |
Rigel Pharmaceuticals, Inc. |
TGF-beta inhibitors
|
|
US10238650B2
(en)
|
2015-03-06 |
2019-03-26 |
Beyondspring Pharmaceuticals, Inc. |
Method of treating cancer associated with a RAS mutation
|
|
SG11201707128TA
(en)
|
2015-03-06 |
2017-09-28 |
Beyondspring Pharmaceuticals Inc |
Method of treating a brain tumor
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
SG11201707948WA
(en)
|
2015-04-03 |
2017-10-30 |
Bristol Myers Squibb Co |
Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
|
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
KR102740444B1
(ko)
|
2015-04-17 |
2024-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
|
|
US10174113B2
(en)
|
2015-04-28 |
2019-01-08 |
Bristol-Myers Squibb Company |
Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody
|
|
WO2016176504A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
|
ES2815683T3
(es)
|
2015-05-11 |
2021-03-30 |
Bristol Myers Squibb Co |
Compuestos tricíclicos como agentes antineoplásicos
|
|
ES2770349T3
(es)
|
2015-05-12 |
2020-07-01 |
Bristol Myers Squibb Co |
Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
ES2739749T3
(es)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
|
AU2016263808B2
(en)
|
2015-05-21 |
2019-01-03 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
WO2016191751A1
(en)
|
2015-05-28 |
2016-12-01 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
PT3303396T
(pt)
|
2015-05-29 |
2023-01-30 |
Bristol Myers Squibb Co |
Anticorpos contra ox40 e utilizações dos mesmos
|
|
US11078278B2
(en)
|
2015-05-29 |
2021-08-03 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
US20180153884A1
(en)
|
2015-05-31 |
2018-06-07 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
CN108026173A
(zh)
|
2015-06-12 |
2018-05-11 |
百时美施贵宝公司 |
通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
FI3313441T3
(fi)
|
2015-06-24 |
2024-03-28 |
Janssen Biotech Inc |
Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
ES2910035T3
(es)
|
2015-07-13 |
2022-05-11 |
Beyondspring Pharmaceuticals Inc |
Composiciones de plinabulina
|
|
CN108368170B
(zh)
|
2015-07-13 |
2022-04-15 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
EP4679094A2
(en)
|
2015-07-14 |
2026-01-14 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
|
|
KR20180034548A
(ko)
|
2015-07-28 |
2018-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
HK1254450A1
(zh)
|
2015-08-07 |
2019-07-19 |
Pieris Pharmaceuticals Gmbh |
对lag-3和pd-1特异性的新型融合多肽
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
RU2020124273A
(ru)
|
2015-08-11 |
2020-12-03 |
Уси Байолоджикс (Кайман) Инк. |
Новые анти-pd-1 антитела
|
|
CN106432494B9
(zh)
*
|
2015-08-11 |
2022-02-15 |
广州誉衡生物科技有限公司 |
新型抗-pd-1抗体
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
JP2018525415A
(ja)
|
2015-08-25 |
2018-09-06 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｇｆベータ受容体アンタゴニスト
|
|
KR102434314B1
(ko)
|
2015-09-01 |
2022-08-19 |
아게누스 인코포레이티드 |
항-pd-1 항체 및 이를 이용하는 방법
|
|
EA201890790A1
(ru)
*
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
|
KR20180053738A
(ko)
|
2015-09-30 |
2018-05-23 |
얀센 바이오테크 인코포레이티드 |
인간 cd40과 특이적으로 결합하는 길항적 항체 및 사용 방법
|
|
RU2746409C1
(ru)
*
|
2015-10-02 |
2021-04-13 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к pd1 и способы их применения
|
|
PL3356411T3
(pl)
*
|
2015-10-02 |
2021-12-06 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiste dla PD1 i TIM3
|
|
AU2016334041B2
(en)
|
2015-10-08 |
2023-02-09 |
Macrogenics, Inc. |
Combination therapy for the treatment of cancer
|
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
|
EP3365062B1
(en)
|
2015-10-19 |
2024-09-18 |
CG Oncology, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
|
KR20180069903A
(ko)
|
2015-11-02 |
2018-06-25 |
파이브 프라임 테라퓨틱스, 인크. |
Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도
|
|
HUE057837T2
(hu)
|
2015-11-03 |
2022-06-28 |
Janssen Biotech Inc |
PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
KR102683841B1
(ko)
*
|
2015-11-17 |
2024-07-10 |
쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 |
Pd-l1 항체, 이의 항원-결합 단편 및 이의 약제학적 용도
|
|
CN106699889A
(zh)
*
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技（上海）有限公司 |
抗pd-1抗体及其治疗用途
|
|
US11072657B2
(en)
|
2015-11-18 |
2021-07-27 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
|
|
SG11201803817PA
(en)
|
2015-11-19 |
2018-06-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
WO2017091580A1
(en)
|
2015-11-23 |
2017-06-01 |
Five Prime Therapeutics, Inc. |
Predicting response to cancer treatment with fgfr2 inhibitors
|
|
MX2018006385A
(es)
|
2015-11-25 |
2019-09-11 |
Visterra Inc |
Moleculas de anticuerpo contra april y usos de las mismas.
|
|
CR20180318A
(es)
|
2015-12-14 |
2018-09-19 |
Macrogenics Inc |
Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
|
|
CN108602829A
(zh)
|
2015-12-15 |
2018-09-28 |
百时美施贵宝公司 |
Cxcr4受体拮抗剂
|
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
|
KR20180089444A
(ko)
|
2015-12-22 |
2018-08-08 |
리제너론 파아마슈티컬스, 인크. |
암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합
|
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
US20190178888A1
(en)
|
2016-01-11 |
2019-06-13 |
Technion Research & Development Foundation Limited |
Methods of determining prognosis of sepsis and treating same
|
|
SG11201805831RA
(en)
|
2016-01-21 |
2018-08-30 |
Innate Pharma |
Neutralization of inhibitory pathways in lymphocytes
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
EP3405497A2
(en)
|
2016-01-22 |
2018-11-28 |
Mabquest SA |
Immunological reagents
|
|
EP3411407B1
(en)
|
2016-02-05 |
2024-04-03 |
Orionis Biosciences BV |
Bispecific signaling agents and uses thereof
|
|
BR112018016054A2
(pt)
|
2016-02-08 |
2019-02-12 |
Beyondspring Pharmaceuticals, Inc. |
composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
|
|
CA3012294A1
(en)
|
2016-02-17 |
2017-08-24 |
Novartis Ag |
Tgfbeta 2 antibodies
|
|
KR20230038311A
(ko)
|
2016-03-04 |
2023-03-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
EP3426688A1
(en)
|
2016-03-08 |
2019-01-16 |
Innate Pharma |
Siglec neutralizing antibodies
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
CN109310885B
(zh)
|
2016-03-15 |
2022-05-31 |
梅尔莎纳医疗公司 |
NaPi2b靶向抗体-药物缀合物及其使用方法
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
EP3433275A1
(en)
|
2016-03-24 |
2019-01-30 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
WO2017167921A1
(en)
|
2016-03-30 |
2017-10-05 |
Centre Léon-Bérard |
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
|
WO2017176925A1
(en)
|
2016-04-05 |
2017-10-12 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
|
|
WO2017184619A2
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
WO2017192813A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
KR20190003687A
(ko)
|
2016-05-04 |
2019-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
|
EP3452452A4
(en)
|
2016-05-04 |
2019-10-30 |
Bristol-Myers Squibb Company |
INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
|
|
US10696648B2
(en)
|
2016-05-04 |
2020-06-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2017192840A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
AR108377A1
(es)
*
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
US11753463B2
(en)
|
2016-05-13 |
2023-09-12 |
Orionis Biosciences BV |
Therapeutic targeting of non-cellular structures
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
CN105968200B
(zh)
*
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
CN106008714B
(zh)
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
|
MY195089A
(en)
|
2016-05-27 |
2023-01-10 |
Agenus Inc |
Anti-Tim-3 Antibodies and Methods of use thereof
|
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
|
SG11201810454YA
(en)
|
2016-06-02 |
2018-12-28 |
Bristol Myers Squibb Co |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
|
EP3463457B1
(en)
|
2016-06-02 |
2023-06-28 |
Bristol-Myers Squibb Company |
Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
|
|
EP4386005A3
(en)
|
2016-06-03 |
2024-09-04 |
Bristol-Myers Squibb Company |
Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
|
|
KR102515509B1
(ko)
|
2016-06-03 |
2023-03-28 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
|
|
KR20230118713A
(ko)
|
2016-06-03 |
2023-08-11 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
|
|
MX389200B
(es)
|
2016-06-06 |
2025-03-20 |
Beyondspring Pharmaceuticals Inc |
Composición y método para reducir la neutropenia.
|
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
MX2019000252A
(es)
|
2016-06-30 |
2019-10-09 |
Oncorus Inc |
Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
|
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
|
WO2018009916A1
(en)
|
2016-07-07 |
2018-01-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antibody adjuvant conjugates
|
|
KR102899060B1
(ko)
|
2016-07-14 |
2025-12-12 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체 및 그의 용도
|
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
EP3497128A2
(en)
|
2016-08-09 |
2019-06-19 |
Kymab Limited |
Anti-icos antibodies
|
|
CA3034326A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
|
WO2018039131A1
(en)
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
CN106977602B
(zh)
*
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN109843322A
(zh)
|
2016-08-26 |
2019-06-04 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
US20190218294A1
(en)
|
2016-09-09 |
2019-07-18 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
|
JP2019531284A
(ja)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
|
|
CN110035769A
(zh)
|
2016-09-21 |
2019-07-19 |
奈斯科尔公司 |
针对siglec-15的抗体及其使用方法
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
BR112019006074A2
(pt)
|
2016-09-29 |
2019-06-18 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo
|
|
IL265800B2
(en)
|
2016-10-11 |
2023-10-01 |
Agenus Inc |
Anti-LAG-3 antibodies and methods of using them
|
|
EP3529264B1
(en)
|
2016-10-24 |
2022-03-09 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
|
US20190315865A1
(en)
|
2016-10-28 |
2019-10-17 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
|
WO2018083087A2
(en)
|
2016-11-02 |
2018-05-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Binding proteins
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
JP7039582B2
(ja)
|
2016-11-03 |
2022-03-22 |
ブリストル－マイヤーズ スクイブ カンパニー |
活性化可能な抗ｃｔｌａ－４抗体およびその使用
|
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
|
TN2019000161A1
(en)
|
2016-11-18 |
2020-10-05 |
Beijing Hanmi Pharmaceutical Co Ltd |
Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
TW201825119A
(zh)
|
2016-11-30 |
2018-07-16 |
日商協和醱酵麒麟有限公司 |
使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
|
|
WO2018106864A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
PT3551660T
(pt)
|
2016-12-07 |
2023-11-30 |
Ludwig Inst For Cancer Res Ltd |
Anticorpos anti-ctla-4 e métodos de uso dos mesmos
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
RU2766582C2
(ru)
*
|
2016-12-23 |
2022-03-15 |
Ремд Биотерапьютикс, Инк. |
Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
|
|
CN113480530A
(zh)
|
2016-12-26 |
2021-10-08 |
阿里根公司 |
芳香烃受体调节剂
|
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
AU2018205730B2
(en)
|
2017-01-05 |
2024-05-30 |
Centre Leon Berard |
Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
|
CN110431135A
(zh)
|
2017-01-06 |
2019-11-08 |
大连万春布林医药有限公司 |
微管蛋白结合化合物及其治疗用途
|
|
AU2018207172B2
(en)
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
CN110167967B
(zh)
*
|
2017-01-18 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
针对抗pd-l1抗体的独特型抗体及其用途
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
WO2018134681A1
(en)
|
2017-01-20 |
2018-07-26 |
Sanofi |
Anti-tgf-beta antibodies and their use
|
|
TWI856437B
(zh)
|
2017-01-20 |
2024-09-21 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
|
UA126863C2
(uk)
|
2017-01-20 |
2023-02-15 |
Аркус Байосайєнсіз, Інк. |
Азолопіримідини для лікування ракових захворювань
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
KR20190109479A
(ko)
|
2017-02-01 |
2019-09-25 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
호중구감소증의 감소 방법
|
|
EP3577138A1
(en)
|
2017-02-06 |
2019-12-11 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
EP3576765B1
(en)
|
2017-02-06 |
2025-07-16 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
MX2019009255A
(es)
|
2017-02-06 |
2019-11-05 |
Orionis Biosciences Nv |
Proteínas quiméricas dirigidas y sus usos.
|
|
CN110290808B
(zh)
|
2017-02-10 |
2023-07-11 |
诺华股份有限公司 |
1-(4-氨基-5-溴-6-(1h-吡唑-1-基)嘧啶-2-基)-1h-吡唑-4-醇及其在治疗癌症中的用途
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
WO2018156740A1
(en)
|
2017-02-24 |
2018-08-30 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
BR112019017743A2
(pt)
|
2017-02-28 |
2020-04-07 |
Sanofi Sa |
rna terapêutico
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
CN110382544B
(zh)
|
2017-03-16 |
2023-12-22 |
先天制药公司 |
用于治疗癌症的组合物和方法
|
|
WO2018183928A1
(en)
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
US20200031944A1
(en)
|
2017-03-31 |
2020-01-30 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
JP7579703B2
(ja)
*
|
2017-04-01 |
2024-11-08 |
北京韓美薬品有限公司 |
抗ｐｄ－ｌ１／抗ｐｄ－１天然抗体構造様ヘテロダイマー二重特異性抗体およびその調製方法
|
|
EP3606946B1
(en)
|
2017-04-03 |
2022-08-24 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
IL268527B2
(en)
|
2017-04-05 |
2024-03-01 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
KR20240017409A
(ko)
|
2017-04-13 |
2024-02-07 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
CN106939049B
(zh)
*
|
2017-04-20 |
2019-10-01 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
|
|
AU2018253950A1
(en)
|
2017-04-20 |
2019-09-19 |
Adc Therapeutics Sa |
Combination therapy with an anti-CD25 antibody-drug conjugate
|
|
JP7408396B2
(ja)
|
2017-04-20 |
2024-01-05 |
アーデーセー セラピューティクス ソシエテ アノニム |
併用療法
|
|
AU2018256459B2
(en)
|
2017-04-21 |
2023-12-07 |
Ikena Oncology, Inc. |
Indole AHR inhibitors and uses thereof
|
|
KR102721597B1
(ko)
|
2017-04-26 |
2024-10-23 |
브리스톨-마이어스 스큅 컴퍼니 |
디술피드 결합 환원을 최소화하는 항체 생산 방법
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
TWI805582B
(zh)
|
2017-05-01 |
2023-06-21 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體類和使用彼等之方法
|
|
IL300964A
(en)
|
2017-05-12 |
2023-04-01 |
Harpoon Therapeutics Inc |
mesothelin binding proteins
|
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP7274426B2
(ja)
|
2017-05-16 |
2023-05-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｇｉｔｒアゴニスト抗体での癌の処置
|
|
PL3634417T3
(pl)
|
2017-05-17 |
2023-09-25 |
Arcus Biosciences, Inc. |
Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
JP7762498B2
(ja)
|
2017-05-25 |
2025-10-30 |
ブリストル－マイヤーズ スクイブ カンパニー |
修飾重鎖定常領域を含む抗体
|
|
PT3631454T
(pt)
|
2017-05-30 |
2023-11-23 |
Bristol Myers Squibb Co |
Tratamento de tumores positivos para lag-3
|
|
AU2018277559A1
(en)
|
2017-05-30 |
2019-10-17 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
|
|
EP3630179A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
|
EP3630838A1
(en)
|
2017-06-01 |
2020-04-08 |
CytomX Therapeutics, Inc. |
Activatable anti-pdl1 antibodies, and methods of use thereof
|
|
CN110678483B
(zh)
|
2017-06-01 |
2023-09-22 |
百时美施贵宝公司 |
用抗pd-1抗体治疗肿瘤的方法
|
|
CN118994394A
(zh)
|
2017-06-12 |
2024-11-22 |
蓝鳍生物医药公司 |
抗-il1rap抗体和抗体药物缀合物
|
|
BR112019026564A2
(pt)
|
2017-06-14 |
2020-06-30 |
Adc Therapeutics Sa |
regimes de dosagem para a administração de um adc anti-cd19
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
WO2018234879A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN110769827A
(zh)
|
2017-06-23 |
2020-02-07 |
博笛生物科技有限公司 |
药物组合物
|
|
KR102757960B1
(ko)
|
2017-06-26 |
2025-01-22 |
베이진 엘티디 |
간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
|
|
JP7012384B2
(ja)
|
2017-06-27 |
2022-02-14 |
ニューラクル サイエンス カンパニー リミテッド |
癌治療のための抗ｆａｍ１９ａ５抗体の用途
|
|
JP2020525483A
(ja)
|
2017-06-27 |
2020-08-27 |
ノバルティス アーゲー |
抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
|
|
EP3421494A1
(en)
|
2017-06-29 |
2019-01-02 |
Sanofi |
Use of isatuximab in combination with an anti-pd-1 antibody
|
|
SG11201911937UA
(en)
|
2017-06-30 |
2020-01-30 |
Bristol Myers Squibb Co |
Amorphous and crystalline forms of ido inhibitors
|
|
CN111094350B
(zh)
|
2017-07-06 |
2024-09-03 |
美勒斯公司 |
调节由细胞表达的生物活性的抗体
|
|
WO2019011855A1
(en)
|
2017-07-10 |
2019-01-17 |
Innate Pharma |
ANTIBODIES NEUTRALIZING SIGLEC-9
|
|
CN111793060B
(zh)
|
2017-07-14 |
2023-06-06 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
IL319798A
(en)
|
2017-07-20 |
2025-05-01 |
Novartis Ag |
ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
|
|
US11401299B2
(en)
|
2017-07-21 |
2022-08-02 |
Novimmune Sa |
Generating multispecific antibody mixtures and methods of uses thereof
|
|
KR102709265B1
(ko)
|
2017-07-28 |
2024-09-23 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
US11899017B2
(en)
|
2017-07-28 |
2024-02-13 |
Bristol-Myers Squibb Company |
Predictive peripheral blood biomarker for checkpoint inhibitors
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
MX2020001451A
(es)
|
2017-08-07 |
2020-08-06 |
Amgen Inc |
Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico.
|
|
US10696650B2
(en)
|
2017-08-17 |
2020-06-30 |
Ikena Oncology, Inc. |
AHR inhibitors and uses thereof
|
|
WO2019040780A1
(en)
|
2017-08-25 |
2019-02-28 |
Five Prime Therapeutics Inc. |
ANTI-B7-H4 ANTIBODIES AND METHODS OF USE
|
|
CA3078605A1
(en)
|
2017-08-28 |
2019-03-07 |
Bristol-Myers Squibb Company |
Tim-3 antagonists for the treatment and diagnosis of cancers
|
|
EP3676278B1
(en)
|
2017-08-31 |
2023-04-12 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
ES2904317T3
(es)
|
2017-08-31 |
2022-04-04 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticancerosos
|
|
US11667663B2
(en)
|
2017-08-31 |
2023-06-06 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
KR20200052327A
(ko)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
|
|
US11021540B2
(en)
|
2017-09-07 |
2021-06-01 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP4624467A2
(en)
|
2017-09-22 |
2025-10-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11351163B2
(en)
|
2017-09-29 |
2022-06-07 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
SG11202002192QA
(en)
|
2017-10-06 |
2020-04-29 |
Innate Pharma |
Restoration of t cell activity via the cd39/cd73 axis
|
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
|
EP3694867B1
(en)
|
2017-10-10 |
2025-12-24 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
FI3694529T3
(fi)
|
2017-10-13 |
2024-09-17 |
Harpoon Therapeutics Inc |
Trispesifiset proteiinit ja niiden käyttömenetelmät
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2019079261A1
(en)
|
2017-10-16 |
2019-04-25 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
CN111556876B
(zh)
|
2017-10-27 |
2024-10-18 |
辉瑞公司 |
对cd123具有特异性的抗体和抗体-药物缀合物及其用途
|
|
KR20200074214A
(ko)
|
2017-11-01 |
2020-06-24 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
|
|
WO2019090002A1
(en)
*
|
2017-11-02 |
2019-05-09 |
Systimmune, Inc. |
Bispecific antibodies and methods of making and using thereof
|
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
|
CN111527084B
(zh)
|
2017-11-06 |
2023-07-18 |
百时美施贵宝公司 |
可用作hpk1抑制剂的异呋喃酮化合物
|
|
WO2019090330A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
KR20200089718A
(ko)
|
2017-11-20 |
2020-07-27 |
아리아젠, 인크. |
인돌 화합물 및 이의 용도
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
RU2020121458A
(ru)
|
2017-11-30 |
2021-12-30 |
Новартис Аг |
Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
|
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
CN115925943A
(zh)
*
|
2017-12-27 |
2023-04-07 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
JP2021508477A
(ja)
|
2017-12-29 |
2021-03-11 |
オンコラス， インコーポレイテッド |
治療用ポリペプチドの腫瘍溶解性ウイルス送達
|
|
WO2019136112A1
(en)
|
2018-01-05 |
2019-07-11 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11324774B2
(en)
|
2018-01-05 |
2022-05-10 |
Augusta University Research Institute, Inc. |
Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
JP2021510697A
(ja)
|
2018-01-12 |
2021-04-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
がん処置のための坑ｉｌ−８抗体及び坑ｐｄ−１抗体を用いる組合せ治療
|
|
KR20250078626A
(ko)
|
2018-01-12 |
2025-06-02 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체 및 그의 용도
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
CN111868091A
(zh)
|
2018-01-16 |
2020-10-30 |
百时美施贵宝公司 |
用抗tim3抗体治疗癌症的方法
|
|
MX2020007526A
(es)
|
2018-01-22 |
2020-09-09 |
Bristol Myers Squibb Co |
Composiciones y metodos para tratar el cancer.
|
|
CA3096287A1
(en)
|
2018-01-22 |
2019-07-25 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019147615A1
(en)
|
2018-01-24 |
2019-08-01 |
Beyondspring Pharmaceuticals, Inc. |
Composition and method for reducing thrombocytopenia via the administration of plinabulin
|
|
US20200354424A1
(en)
|
2018-01-26 |
2020-11-12 |
Orionis Biosciences, Inc. |
Xcr1 binding agents and uses thereof
|
|
MX2020007797A
(es)
|
2018-01-29 |
2020-09-18 |
Merck Patent Gmbh |
Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
|
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
KR102877915B1
(ko)
|
2018-02-05 |
2025-10-29 |
오리오니스 바이오사이언시즈 인코포레이티드 |
섬유아세포 결합제 및 이의 용도
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
WO2019157124A1
(en)
|
2018-02-08 |
2019-08-15 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
US11478479B2
(en)
|
2018-02-16 |
2022-10-25 |
Arcus Biosciences, Inc. |
Dosing with an azolopyrimidine compound
|
|
AU2019226011B2
(en)
|
2018-02-21 |
2025-11-27 |
Five Prime Therapeutics, Inc. |
B7-H4 antibody formulations
|
|
EP3755725A1
(en)
|
2018-02-23 |
2020-12-30 |
BicycleTX Limited |
Multimeric bicyclic peptide ligands
|
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
|
CN111971308A
(zh)
|
2018-03-02 |
2020-11-20 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
|
PE20210452A1
(es)
|
2018-03-05 |
2021-03-08 |
Arcus Biosciences Inc |
Inhibidores de la arginasa
|
|
US11945834B2
(en)
|
2018-03-08 |
2024-04-02 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019183040A1
(en)
|
2018-03-21 |
2019-09-26 |
Five Prime Therapeutics, Inc. |
ANTIBODIES BINDING TO VISTA AT ACIDIC pH
|
|
AU2019236865A1
(en)
|
2018-03-23 |
2020-10-01 |
Bristol-Myers Squibb Company |
Antibodies against MICA and/or MICB and uses thereof
|
|
KR20200139724A
(ko)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
|
SG11202009839PA
(en)
|
2018-04-12 |
2020-11-27 |
Bristol Myers Squibb Co |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
AU2019255196A1
(en)
|
2018-04-16 |
2020-11-12 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
|
AU2019261582A1
(en)
|
2018-04-25 |
2020-11-12 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
CN112218883A
(zh)
|
2018-04-26 |
2021-01-12 |
艾吉纳斯公司 |
热休克蛋白结合肽组合物及其使用方法
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
|
CA3097620A1
(en)
|
2018-05-04 |
2019-11-07 |
Tollys |
Tlr3 ligands that activate both epithelial and myeloid cells
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019232319A1
(en)
|
2018-05-31 |
2019-12-05 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting cd73
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
CN115991787A
(zh)
|
2018-06-05 |
2023-04-21 |
江苏康宁杰瑞生物制药有限公司 |
二聚体及其用途
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
AU2019289646B2
(en)
|
2018-06-18 |
2025-10-23 |
Innate Pharma |
Compositions and methods for treating cancer
|
|
EP4349411A3
(en)
|
2018-06-20 |
2024-06-19 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
PE20210469A1
(es)
|
2018-06-27 |
2021-03-08 |
Bristol Myers Squibb Co |
Compuestos de naftiridinona sustituidos utiles como activadores de celulas t
|
|
CN112585139B
(zh)
|
2018-06-27 |
2023-12-01 |
百时美施贵宝公司 |
用作t细胞激活剂的萘啶酮化合物
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI819024B
(zh)
|
2018-07-09 |
2023-10-21 |
美商戊瑞治療有限公司 |
結合至ｉｌｔ４的抗體
|
|
MX2021000309A
(es)
|
2018-07-10 |
2021-04-12 |
Novartis Ag |
Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-dion a y su uso en el tratamiento de enfermedades dependientes del dedo de zinc 2 de la familia ikaros (ikzf2).
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CA3104536A1
(en)
|
2018-07-11 |
2020-01-16 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
CA3106366A1
(en)
|
2018-07-18 |
2020-01-23 |
Arcus Biosciences, Inc. |
Solid forms of an azolopyrimidine compound
|
|
JP2021530502A
(ja)
|
2018-07-18 |
2021-11-11 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
|
|
WO2020018879A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
US12145927B2
(en)
|
2018-07-23 |
2024-11-19 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
KR20210040080A
(ko)
|
2018-07-26 |
2021-04-12 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 lag-3 조합 요법
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
CN113038989A
(zh)
|
2018-08-16 |
2021-06-25 |
先天肿瘤免疫公司 |
咪唑并[4,5-c]喹啉衍生的nlrp3调节剂
|
|
ES2974964T3
(es)
|
2018-08-16 |
2024-07-02 |
Innate Tumor Immunity Inc |
Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
|
|
EP3837245A1
(en)
|
2018-08-16 |
2021-06-23 |
Innate Tumor Immunity, Inc. |
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
|
WO2020041655A1
(en)
|
2018-08-24 |
2020-02-27 |
Sanofi |
Therapeutic rna for solid tumor cancers
|
|
EP3843849A1
(en)
|
2018-08-27 |
2021-07-07 |
Pieris Pharmaceuticals GmbH |
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
KR20210089146A
(ko)
|
2018-09-19 |
2021-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
EP3864046A1
(en)
|
2018-10-09 |
2021-08-18 |
Bristol-Myers Squibb Company |
Anti-mertk antibodies for treating cancer
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
|
EP3867409A1
(en)
|
2018-10-16 |
2021-08-25 |
Novartis AG |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
|
CA3117016A1
(en)
|
2018-10-19 |
2020-04-23 |
Bristol-Myers Squibb Company |
Combination therapy for melanoma
|
|
CN112912403A
(zh)
|
2018-10-23 |
2021-06-04 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
JP2022513400A
(ja)
|
2018-10-29 |
2022-02-07 |
メルサナ セラピューティクス インコーポレイテッド |
ペプチド含有リンカーを有するシステイン操作抗体－薬物コンジュゲート
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
EP3890773A4
(en)
|
2018-11-08 |
2022-11-09 |
Orionis Biosciences, Inc. |
MODULATION OF DENDRITIC CELL LINES
|
|
EP3876955A4
(en)
|
2018-11-09 |
2022-08-24 |
Pierian Biosciences, LLC |
METHODS AND COMPOSITIONS FOR DETERMINING THE COMPOSITION OF A TUMOR MICROENVIRONMENT
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
EP3880231A1
(en)
|
2018-11-16 |
2021-09-22 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
CN113316590B
(zh)
|
2018-11-16 |
2025-02-28 |
百时美施贵宝公司 |
抗nkg2a抗体及其用途
|
|
AU2019379808C1
(en)
|
2018-11-16 |
2024-01-25 |
Arcus Biosciences, Inc. |
Inhibitors of ARG1 and/or ARG2
|
|
TW202038943A
(zh)
|
2018-11-19 |
2020-11-01 |
美商雅里俊公司 |
治療癌症之方法
|
|
WO2020112781A1
(en)
|
2018-11-28 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
KR102891608B1
(ko)
|
2018-11-30 |
2025-11-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
|
CA3119807A1
(en)
|
2018-12-04 |
2020-06-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
EP3666905A1
(en)
|
2018-12-11 |
2020-06-17 |
Sanofi |
E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
|
|
MX2021006831A
(es)
|
2018-12-11 |
2021-07-02 |
Theravance Biopharma R&D Ip Llc |
Inhibidores de alk5.
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
EP3898674A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
BR112021011351A2
(pt)
|
2018-12-21 |
2021-11-16 |
Novartis Ag |
Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
|
|
EP3897849A1
(en)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
WO2020127965A1
(en)
|
2018-12-21 |
2020-06-25 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
WO2020136133A1
(en)
|
2018-12-23 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Tumor classification based on predicted tumor mutational burden
|
|
CN111423510B
(zh)
|
2019-01-10 |
2024-02-06 |
迈威(上海)生物科技股份有限公司 |
重组抗人pd-1抗体及其应用
|
|
WO2020150113A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
|
|
WO2020150114A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators, for use in the treatment of cancer
|
|
JP7506080B2
(ja)
|
2019-01-14 |
2024-06-25 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
|
EP3911641A1
(en)
|
2019-01-14 |
2021-11-24 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
CN113645960B
(zh)
|
2019-01-17 |
2024-12-06 |
佐治亚技术研究公司 |
含有氧化的胆固醇的药物递送系统
|
|
AU2020210614A1
(en)
|
2019-01-21 |
2021-08-26 |
Sanofi |
Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
|
|
TW202045172A
(zh)
|
2019-02-12 |
2020-12-16 |
瑞士商諾華公司 |
包含tno155和pd-1抑制劑之藥物組合
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
|
US20220107320A1
(en)
|
2019-02-15 |
2022-04-07 |
Incelldx, Inc. |
Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
|
|
BR112021015323A2
(pt)
|
2019-02-27 |
2021-10-05 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de malat1
|
|
KR20210137162A
(ko)
|
2019-03-12 |
2021-11-17 |
아르커스 바이오사이언시즈 인코포레이티드 |
종양유전자-유발 암의 치료
|
|
CA3130794A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
CN120131907A
(zh)
|
2019-03-19 |
2025-06-13 |
瓦尔希伯伦私人肿瘤研究基金会 |
采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
JP7547360B2
(ja)
|
2019-03-22 |
2024-09-09 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
US20220041733A1
(en)
|
2019-03-28 |
2022-02-10 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN113874397A
(zh)
|
2019-03-29 |
2021-12-31 |
艾库斯生物科学有限公司 |
利用鉴定的腺苷指纹治疗癌症
|
|
EP3946462A1
(en)
|
2019-04-02 |
2022-02-09 |
BicycleTX Limited |
Bicycle toxin conjugates and uses thereof
|
|
KR20220006139A
(ko)
|
2019-04-05 |
2022-01-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
JP7595024B2
(ja)
|
2019-04-15 |
2024-12-05 |
アリアジェン，インコーポレイテッド |
キラルインドール化合物およびその使用
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
TW202043291A
(zh)
|
2019-04-19 |
2020-12-01 |
美商建南德克公司 |
抗mertk抗體及使用方法
|
|
EP3959239A1
(en)
|
2019-04-23 |
2022-03-02 |
Innate Pharma |
Cd73 blocking antibodies
|
|
CA3133821A1
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
SG11202111262XA
(en)
|
2019-05-13 |
2021-11-29 |
Regeneron Pharma |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
|
KR20220016156A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
|
|
CN114174537A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
细胞定位特征和组合疗法
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
CA3141826A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
JP2022537324A
(ja)
|
2019-06-18 |
2022-08-25 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ
|
|
KR20220041080A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
|
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021026179A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
JP7771749B2
(ja)
*
|
2019-08-08 |
2025-11-18 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
GB201912107D0
(en)
|
2019-08-22 |
2019-10-09 |
Amazentis Sa |
Combination
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
PE20221151A1
(es)
|
2019-08-30 |
2022-07-18 |
Agenus Inc |
Anticuerpos anti-cd96 y sus metodos de uso
|
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
EP4031531A1
(en)
|
2019-09-17 |
2022-07-27 |
Bial-R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
|
CA3151022A1
(en)
|
2019-09-17 |
2021-03-25 |
Bial - R&D Investments, S.A. |
Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
|
JP2022549227A
(ja)
|
2019-09-17 |
2022-11-24 |
バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ |
医学的障害の治療における使用のための置換された飽和および不飽和ｎ－複素環式カルボキサミドおよび関連化合物
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
WO2021055698A1
(en)
|
2019-09-19 |
2021-03-25 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
BR112022004316A2
(pt)
|
2019-09-22 |
2022-06-21 |
Bristol Myers Squibb Co |
Caracterização espacial quantitativa para terapia de antagonista lag-3
|
|
KR20220069964A
(ko)
|
2019-09-25 |
2022-05-27 |
씨젠 인크. |
조혈암의 치료를 위한 항-cd30 adc, 항-pd-1 및 화학치료제 조합
|
|
CA3152263A1
(en)
|
2019-09-25 |
2021-04-01 |
Julia SANTUCCI PEREIRA DEL BUONO |
Composite biomarker for cancer therapy
|
|
JP2022550783A
(ja)
|
2019-09-30 |
2022-12-05 |
アストラゼネカ・アクチエボラーグ |
併用処置
|
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
MX2022004766A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Terapias combinadas con venetoclax e inhibidores de tim-3.
|
|
KR20220087498A
(ko)
|
2019-10-21 |
2022-06-24 |
노파르티스 아게 |
Tim-3 억제제 및 그의 용도
|
|
CN114599372A
(zh)
|
2019-11-04 |
2022-06-07 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的组合疗法
|
|
MX2022005376A
(es)
|
2019-11-04 |
2022-05-19 |
Alector Llc |
Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.
|
|
KR20220092578A
(ko)
|
2019-11-05 |
2022-07-01 |
브리스톨-마이어스 스큅 컴퍼니 |
M-단백질 검정 및 이의 용도
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
KR20220093349A
(ko)
|
2019-11-08 |
2022-07-05 |
브리스톨-마이어스 스큅 컴퍼니 |
흑색종에 대한 lag-3 길항제 요법
|
|
JP7629916B2
(ja)
|
2019-11-13 |
2025-02-14 |
ジェネンテック， インコーポレイテッド |
治療用化合物および使用方法
|
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
MX2022005839A
(es)
|
2019-11-19 |
2022-06-09 |
Bristol Myers Squibb Co |
Compuestos utiles como inhibidores de la proteina helios.
|
|
CN114728941A
(zh)
|
2019-11-22 |
2022-07-08 |
施万生物制药研发Ip有限责任公司 |
作为alk5抑制剂的经取代的1,5-萘啶或喹啉
|
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
MX2022006134A
(es)
|
2019-11-26 |
2022-06-17 |
Bristol Myers Squibb Co |
Sales/cocristales de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroqu inolin-4-il)ciclohexil)propanamida.
|
|
CA3159317A1
(en)
|
2019-11-26 |
2021-06-03 |
Alfredo C. Castro |
Polymorphic carbazole derivatives and uses thereof
|
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
MX2022006891A
(es)
|
2019-12-09 |
2022-09-09 |
Seagen Inc |
Terapia combinada con liv1-adc y antagonista de pd-1.
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220118481A
(ko)
|
2019-12-19 |
2022-08-25 |
브리스톨-마이어스 스큅 컴퍼니 |
Dgk 억제제 및 체크포인트 길항제의 조합물
|
|
IL293834A
(en)
|
2019-12-20 |
2022-08-01 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
CN115175907B
(zh)
|
2019-12-23 |
2024-08-02 |
百时美施贵宝公司 |
可用作t细胞激活剂的经取代的哌嗪衍生物
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
WO2021133920A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
AU2020412472A1
(en)
|
2019-12-23 |
2022-08-18 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as T cell activators
|
|
US12492172B2
(en)
|
2019-12-23 |
2025-12-09 |
Bristol-Myers Squibb Company |
Substituted quinazolinyl compounds useful as T cell activators
|
|
WO2021133748A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
|
EP4087874A1
(en)
|
2020-01-06 |
2022-11-16 |
HiFiBiO (HK) Limited |
Anti-tnfr2 antibody and uses thereof
|
|
CN115210261B
(zh)
|
2020-01-07 |
2025-07-18 |
高诚生物医药公司 |
抗半乳糖凝集素-9抗体及其用途
|
|
WO2021142203A1
(en)
|
2020-01-10 |
2021-07-15 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
US11534441B2
(en)
|
2020-01-15 |
2022-12-27 |
Blueprint Medicines Corporation |
MAP4K1 inhibitors
|
|
KR20220128389A
(ko)
|
2020-01-17 |
2022-09-20 |
노파르티스 아게 |
골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
|
|
AU2021213767A1
(en)
|
2020-01-28 |
2022-07-28 |
Genentech, Inc. |
IL15/IL15R alpha heterodimeric Fc-fusion proteins for the treatment of cancer
|
|
EP4097234A1
(en)
|
2020-01-28 |
2022-12-07 |
Université de Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021152548A1
(en)
|
2020-01-30 |
2021-08-05 |
Benitah Salvador Aznar |
Combination therapy for treatment of cancer and cancer metastasis
|
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
|
US20230087600A1
(en)
|
2020-02-06 |
2023-03-23 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
CN115515615A
(zh)
|
2020-02-18 |
2022-12-23 |
艾莱克特有限责任公司 |
Pilra抗体及其使用方法
|
|
CA3173356A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor or a pd-1 inhibitor.
|
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
|
US20230085724A1
(en)
|
2020-03-05 |
2023-03-23 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
CN115768465A
(zh)
|
2020-03-06 |
2023-03-07 |
Ona疗法有限公司 |
抗cd36抗体及其治疗癌症的用途
|
|
AU2021230575A1
(en)
|
2020-03-06 |
2022-10-20 |
Celgene Quanticel Research, Inc. |
Combination of an LSD-1 inhibitor and nivolumab for use in treating SCLC or sqNSCLC
|
|
WO2021183428A1
(en)
|
2020-03-09 |
2021-09-16 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
IL296451A
(en)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
Mdm2 degraders and uses thereof
|
|
EP4121409A1
(en)
|
2020-03-19 |
2023-01-25 |
Arcus Biosciences, Inc. |
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
|
|
US20230119066A1
(en)
|
2020-03-23 |
2023-04-20 |
Bristol-Myers Squibb Company |
Anti-ccr8 antibodies for treating cancer
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
CA3172449A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
CN115443269A
(zh)
|
2020-03-31 |
2022-12-06 |
施万生物制药研发Ip有限责任公司 |
经取代的嘧啶和使用方法
|
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
|
WO2021214623A1
(en)
|
2020-04-21 |
2021-10-28 |
Novartis Ag |
Dosing regimen for treating a disease modulated by csf-1r
|
|
SE2050559A1
(en)
*
|
2020-05-13 |
2021-11-14 |
Khs Biomedinvent Ab |
PD-1 as a predictive marker for therapy in cancer
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
PE20231078A1
(es)
|
2020-06-02 |
2023-07-17 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
WO2021253041A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Naphthyridine derivatives useful as alk5 inhibitors
|
|
EP4165169A1
(en)
|
2020-06-11 |
2023-04-19 |
Novartis AG |
Zbtb32 inhibitors and uses thereof
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
EP4172323A1
(en)
|
2020-06-29 |
2023-05-03 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
|
WO2022008519A1
(en)
|
2020-07-07 |
2022-01-13 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
JP2023536462A
(ja)
|
2020-07-30 |
2023-08-25 |
カイメラ セラピューティクス， インコーポレイテッド |
変異体リンパ腫を処置する方法
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3188996A1
(en)
|
2020-08-10 |
2022-02-17 |
Tengfei XIAO |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
|
WO2022036079A1
(en)
|
2020-08-13 |
2022-02-17 |
Bristol-Myers Squibb Company |
Methods of redirecting of il-2 to target cells of interest
|
|
IL300450A
(en)
|
2020-08-17 |
2023-04-01 |
Bicycletx Ltd |
Bicyclic conjugates specific to nectin-4 and uses thereof
|
|
MA71214A
(fr)
|
2020-08-26 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1
|
|
WO2022047189A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
MX2023002326A
(es)
|
2020-08-31 |
2023-03-21 |
Bristol Myers Squibb Co |
Firma de localizacion celular e inmunoterapia.
|
|
JP2023544410A
(ja)
|
2020-10-05 |
2023-10-23 |
ブリストル－マイヤーズ スクイブ カンパニー |
タンパク質を濃縮するための方法
|
|
US20230364127A1
(en)
|
2020-10-06 |
2023-11-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
|
EP4228692A1
(en)
*
|
2020-10-13 |
2023-08-23 |
ImmunoVaccine Technologies Inc. |
Methods of treating diffuse large b-cell lymphoma
|
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
|
|
MX2023004493A
(es)
|
2020-10-23 |
2023-05-10 |
Bristol Myers Squibb Co |
Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon.
|
|
IL302346A
(en)
|
2020-10-28 |
2023-06-01 |
Ikena Oncology Inc |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
AU2021374592A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
JP7762198B2
(ja)
|
2020-11-04 |
2025-10-29 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与
|
|
EP4240766A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
JP7749667B2
(ja)
|
2020-11-13 |
2025-10-06 |
ジェネンテック， インコーポレイテッド |
肺がんを治療するためのｋｒａｓｇ１２ｃ阻害剤及びｐｄ－ｌ１結合アンタゴニストを含む方法及び組成物
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
|
MX2023006488A
(es)
|
2020-12-02 |
2023-06-20 |
Genentech Inc |
Procedimientos y composiciones para el tratamiento neoadyuvante y adyuvante del carcinoma urotelial.
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
MX2023006777A
(es)
|
2020-12-11 |
2023-08-17 |
Univ North Carolina Chapel Hill |
Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
|
|
JP2024501207A
(ja)
|
2020-12-16 |
2024-01-11 |
ゴッサマー バイオ サービシズ、インコーポレイテッド |
Ｔ細胞活性化剤として有用な化合物
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
MX2023007650A
(es)
|
2020-12-28 |
2023-09-11 |
Bristol Myers Squibb Co |
Metodos de tratamiento de tumores.
|
|
DK4267105T3
(da)
|
2020-12-28 |
2025-05-19 |
Bristol Myers Squibb Co |
Antistofsammensætninger og fremgangsmåder til anvendelse deraf
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
CN116745322A
(zh)
|
2021-01-08 |
2023-09-12 |
百时美施贵宝公司 |
使用抗岩藻糖基-gm1抗体的组合疗法
|
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
|
CA3203705A1
(en)
|
2021-01-22 |
2022-07-28 |
Erik Hans MANTING |
Methods of tumor vaccination
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
EP4288430A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
CA3206501A1
(en)
|
2021-02-02 |
2022-08-11 |
Shaun Abbott |
Gpr84 antagonists and uses thereof
|
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
US12252488B2
(en)
|
2021-02-12 |
2025-03-18 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
JP2024506339A
(ja)
|
2021-02-12 |
2024-02-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二環式テトラヒドロアゼピン誘導体
|
|
MX2023009527A
(es)
|
2021-02-15 |
2023-08-24 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
TW202245789A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
EP4305041A1
(en)
|
2021-03-08 |
2024-01-17 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
|
US20250326846A1
(en)
|
2021-03-23 |
2025-10-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
JP2024514245A
(ja)
|
2021-03-29 |
2024-03-29 |
ジュノー セラピューティクス インコーポレイテッド |
チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
|
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
IL307316A
(en)
|
2021-03-31 |
2023-11-01 |
Merus Nv |
New binding regions for PD-1
|
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
JP2024515545A
(ja)
|
2021-04-05 |
2024-04-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
がん治療のためのピリジニル置換オキソイソインドリン化合物
|
|
US11718601B2
(en)
|
2021-04-06 |
2023-08-08 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022217276A1
(en)
|
2021-04-09 |
2022-10-13 |
Nimbus Clio, Inc. |
Cbl-b modulators and uses thereof
|
|
JP2024513505A
(ja)
|
2021-04-09 |
2024-03-25 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
腫瘍を治療するための組成物及び方法
|
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
KR20230172548A
(ko)
|
2021-04-16 |
2023-12-22 |
이케나 온콜로지, 인코포레이티드 |
Mek 억제제 및 이의 용도
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
JP2024516230A
(ja)
|
2021-04-30 |
2024-04-12 |
ジェネンテック， インコーポレイテッド |
がんのための治療及び診断方法並びに組成物
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022243378A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
US20240226115A1
(en)
|
2021-05-21 |
2024-07-11 |
Arcus Biosciences, Inc. |
Axl inhibitor compounds
|
|
WO2022246177A1
(en)
|
2021-05-21 |
2022-11-24 |
Arcus Biosciences, Inc. |
Axl compounds
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
CN117915948A
(zh)
|
2021-06-18 |
2024-04-19 |
建新公司 |
抗TGF-β抗体配制品及其用途
|
|
EP4363059A1
(en)
|
2021-06-29 |
2024-05-08 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
JP2024525381A
(ja)
|
2021-07-02 |
2024-07-12 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
JP2024525758A
(ja)
|
2021-07-13 |
2024-07-12 |
ビオンテック・ソシエタス・エウロパエア |
がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
|
|
CN117940438A
(zh)
|
2021-07-14 |
2024-04-26 |
缆图药品公司 |
作为map4k1抑制剂的杂环化合物
|
|
US20240336630A1
(en)
|
2021-07-15 |
2024-10-10 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
EP4377350A2
(en)
|
2021-07-28 |
2024-06-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
|
JP2024529502A
(ja)
|
2021-07-30 |
2024-08-06 |
オーエヌエー セラピューティクス エセ．エレ． |
抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
WO2023015198A1
(en)
|
2021-08-04 |
2023-02-09 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
|
WO2023020315A1
(zh)
*
|
2021-08-19 |
2023-02-23 |
南京吉盛澳玛生物医药有限公司 |
靶向pd-l1/pd-1的抗体及其应用
|
|
IL310662A
(en)
|
2021-08-23 |
2024-04-01 |
Immunitas Therapeutics Inc |
Anti-CD161 antibodies and their uses
|
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
EP4413040A1
(en)
|
2021-10-06 |
2024-08-14 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023077034A1
(en)
|
2021-10-28 |
2023-05-04 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
US20240417473A1
(en)
|
2021-10-29 |
2024-12-19 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
IL312397A
(en)
|
2021-10-29 |
2024-06-01 |
Kymera Therapeutics Inc |
IRAK4 subunits and their synthesis
|
|
IL312348A
(en)
|
2021-10-29 |
2024-06-01 |
Arcus Biosciences Inc |
HIF-2ALPHA inhibitors and methods of using it
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
MX2024005722A
(es)
|
2021-11-12 |
2024-05-28 |
Novartis Ag |
Terapia de combinacion para el tratamiento del cancer de pulmon.
|
|
US12275745B2
(en)
|
2021-11-24 |
2025-04-15 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
IL313439A
(en)
|
2021-12-16 |
2024-08-01 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023137161A1
(en)
|
2022-01-14 |
2023-07-20 |
Amgen Inc. |
Triple blockade of tigit, cd112r, and pd-l1
|
|
MX2024008831A
(es)
|
2022-01-26 |
2024-07-25 |
Bristol Myers Squibb Co |
Terapia combinada para carcinoma hepatocelular.
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
KR20240137086A
(ko)
|
2022-01-28 |
2024-09-19 |
조지아뮨 인코포레이티드 |
Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
|
|
US12091411B2
(en)
|
2022-01-31 |
2024-09-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
US20250152643A1
(en)
|
2022-02-17 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
|
US20230277669A1
(en)
|
2022-02-24 |
2023-09-07 |
Amazentis Sa |
Uses of urolithins
|
|
CN118765284A
(zh)
|
2022-02-25 |
2024-10-11 |
百时美施贵宝公司 |
结直肠癌的组合疗法
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
US20250179170A1
(en)
|
2022-03-08 |
2025-06-05 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023174210A1
(en)
|
2022-03-14 |
2023-09-21 |
Laekna Limited |
Combination treatment for cancer
|
|
JP2025509749A
(ja)
|
2022-03-18 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
ポリペプチドの単離方法
|
|
EP4504780A1
(en)
|
2022-04-01 |
2025-02-12 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
US20230326022A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
CA3256561A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and their uses
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
KR20250008898A
(ko)
|
2022-05-11 |
2025-01-16 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
|
|
WO2023220703A1
(en)
|
2022-05-12 |
2023-11-16 |
Genentech, Inc. |
Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
|
|
CN119451985A
(zh)
|
2022-05-12 |
2025-02-14 |
健玛保 |
在组合疗法中能够结合cd27的结合剂
|
|
US20250340641A1
(en)
|
2022-05-18 |
2025-11-06 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
CA3252253A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
CA3258064A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
|
|
CN119856056A
(zh)
|
2022-06-07 |
2025-04-18 |
基因泰克公司 |
用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法
|
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
KR20250039386A
(ko)
|
2022-07-13 |
2025-03-20 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법
|
|
EP4554680A1
(en)
|
2022-07-15 |
2025-05-21 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
|
JP2025523845A
(ja)
|
2022-07-19 |
2025-07-25 |
ジェネンテック， インコーポレイテッド |
抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
|
|
WO2024020034A1
(en)
|
2022-07-20 |
2024-01-25 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
|
EP4310197A1
(en)
|
2022-07-21 |
2024-01-24 |
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda |
Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
|
|
KR20250044313A
(ko)
|
2022-07-27 |
2025-03-31 |
아스트라제네카 아베 |
Pd-1/pd-l1 저해제와 인터루킨-12를 발현하는 재조합 바이러스의 조합물
|
|
AU2023317740A1
(en)
|
2022-08-02 |
2025-03-13 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
KR20250057801A
(ko)
|
2022-08-02 |
2025-04-29 |
리미널 바이오사이언시스 리미티드 |
아릴-트라이아졸릴 및 관련 gpr84 길항제 및 이의 용도
|
|
IL318576A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
Pyridoxine-substituted GPR84 antagonists and their uses
|
|
JP2025528134A
(ja)
|
2022-08-08 |
2025-08-26 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔ細胞活性化剤として有用な置換テトラゾリル化合物
|
|
KR20250046310A
(ko)
|
2022-08-09 |
2025-04-02 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물
|
|
IL318163A
(en)
|
2022-08-11 |
2025-03-01 |
Hoffmann La Roche |
TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES
|
|
AR130169A1
(es)
|
2022-08-11 |
2024-11-13 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina bicíclicos
|
|
AR130167A1
(es)
|
2022-08-11 |
2024-11-13 |
Hoffmann La Roche |
Derivados bicíclicos de tetrahidroazepina
|
|
CR20250043A
(es)
|
2022-08-11 |
2025-03-25 |
Hoffmann La Roche |
Derivados bicíclicos de tetrahidrotiazepina
|
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
EP4587001A1
(en)
|
2022-09-14 |
2025-07-23 |
Arcus Biosciences, Inc. |
Dispersions of etrumadenant
|
|
CN120379691A
(zh)
|
2022-09-30 |
2025-07-25 |
爱兰蒂斯疗法股份公司 |
耐药性肝细胞癌的治疗
|
|
WO2024073111A2
(en)
*
|
2022-09-30 |
2024-04-04 |
Adicet Therapeutics, Inc. |
Affinity binding entities directed to b7h6 and methods of use thereof
|
|
EP4599089A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
WO2024077166A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
EP4598946A1
(en)
|
2022-10-05 |
2025-08-13 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024081385A1
(en)
|
2022-10-14 |
2024-04-18 |
Arcus Biosciences, Inc. |
Hpk1 inhibitors and methods of use thereof
|
|
CN119997975A
(zh)
|
2022-10-19 |
2025-05-13 |
安斯泰来制药株式会社 |
抗cldn4-抗cd137双特异性抗体通过与pd-1信号抑制剂的组合在癌症治疗中的应用
|
|
EP4605422A2
(en)
|
2022-10-20 |
2025-08-27 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
WO2024086718A1
(en)
|
2022-10-20 |
2024-04-25 |
Arcus Biosciences, Inc. |
Lyophilized formulations of cd73 compounds
|
|
EP4608995A1
(en)
|
2022-10-24 |
2025-09-03 |
Memorial Sloan-Kettering Cancer Center |
Tumour stratification for responsiveness to an immune checkpoint inhibitor
|
|
WO2024089418A1
(en)
|
2022-10-24 |
2024-05-02 |
Cancer Research Technology Limited |
Tumour sensitisation to checkpoint inhibitors with redox status modifier
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
EP4615480A1
(en)
|
2022-11-07 |
2025-09-17 |
Alector LLC |
Uses of siglec-9 ecd fusion molecules in cancer treatment
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
JP2025541738A
(ja)
|
2022-12-01 |
2025-12-23 |
ビオンテック・ソシエタス・エウロパエア |
抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体
|
|
CN120390652A
(zh)
|
2022-12-01 |
2025-07-29 |
免疫医疗有限公司 |
用于治疗癌症的包含抗pd-l1抗体和抗cd73抗体的组合疗法
|
|
EP4634224A1
(en)
|
2022-12-14 |
2025-10-22 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
KR20250122520A
(ko)
|
2022-12-20 |
2025-08-13 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신을 이용한 췌장암 치료 방법
|
|
AU2023409221A1
(en)
|
2022-12-21 |
2025-06-12 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
AU2023417699A1
(en)
*
|
2022-12-29 |
2025-07-03 |
Development Center For Biotechnology |
Fusion protein targeting pd-l1 and neutralizing gas6 and uses thereof
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
|
EP4649173A1
(en)
|
2023-01-13 |
2025-11-19 |
Akrivia Biomedics Limited |
Method of profiling diseases
|
|
WO2024160721A1
(en)
|
2023-01-30 |
2024-08-08 |
Kymab Limited |
Antibodies
|
|
AU2024225483A1
(en)
|
2023-02-23 |
2025-08-28 |
Imcheck Therapeutics |
Combination of btn3a activating antibody and immune checkpoint inhibitors
|
|
KR20250155054A
(ko)
|
2023-03-13 |
2025-10-29 |
리제너론 파마슈티칼스 인코포레이티드 |
흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024233360A1
(en)
|
2023-05-05 |
2024-11-14 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
|
KR20250019700A
(ko)
|
2023-05-08 |
2025-02-10 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 페닐 옥사졸론 화합물
|
|
AU2024269298A1
(en)
|
2023-05-10 |
2025-11-27 |
Blueprint Medicines Corporation |
Gsk3a inhibitors and methods of use thereof
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
US12410258B2
(en)
|
2023-05-12 |
2025-09-09 |
Ganmab A/S |
Antibodies capable of binding to OX40, variants thereof and uses thereof
|
|
WO2024236048A1
(en)
|
2023-05-16 |
2024-11-21 |
Nh Theraguix |
Combination therapy for treating tumors with radiotherapy
|
|
US20250011318A1
(en)
|
2023-05-25 |
2025-01-09 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
|
WO2024249540A1
(en)
|
2023-05-31 |
2024-12-05 |
Bristol-Myers Squibb Company |
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
|
|
AU2024281414A1
(en)
|
2023-06-02 |
2025-12-11 |
Arcus Biosciences, Inc. |
Biomarkers for predicting cancer treatment efficacy
|
|
WO2024254227A1
(en)
|
2023-06-07 |
2024-12-12 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
WO2024261239A1
(en)
|
2023-06-23 |
2024-12-26 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
AU2024312190A1
(en)
|
2023-06-23 |
2025-07-03 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025006811A1
(en)
|
2023-06-27 |
2025-01-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025038857A1
(en)
|
2023-08-16 |
2025-02-20 |
Arcus Biosciences, Inc. |
TETRALINS TARGETING MUTANT HIF-2α
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
TW202525802A
(zh)
|
2023-09-02 |
2025-07-01 |
美商必治妥美雅史谷比公司 |
經取代之苯基氧代㗁唑基哌啶二酮化合物
|
|
US20250075000A1
(en)
|
2023-09-06 |
2025-03-06 |
Novimmune Sa |
Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
|
|
WO2025054339A1
(en)
|
2023-09-08 |
2025-03-13 |
Arcus Biosciences, Inc. |
Triazolopyridine compounds as inhibitors of kit
|
|
AR133800A1
(es)
|
2023-09-13 |
2025-11-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolinil piperidina-2,6-diona sustituida
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025072330A1
(en)
|
2023-09-26 |
2025-04-03 |
Arcus Biosciences, Inc. |
Kit inhibitor compounds and methods of use thereof
|
|
WO2025076299A1
(en)
|
2023-10-06 |
2025-04-10 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
|
WO2025080538A1
(en)
|
2023-10-09 |
2025-04-17 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025085404A1
(en)
|
2023-10-16 |
2025-04-24 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treating lung cancer
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
US20250145590A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096979A1
(en)
|
2023-11-02 |
2025-05-08 |
Arcus Biosciences, Inc. |
Thiazole compounds as kit inhibitors and methods of use thereof
|
|
WO2025106736A2
(en)
|
2023-11-15 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
|
|
WO2025106278A1
(en)
|
2023-11-17 |
2025-05-22 |
Mersana Therapeutics, Inc. |
Treatment of cancer using b7-h4-targeted antibody-drug conjugates
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025125652A1
(en)
|
2023-12-13 |
2025-06-19 |
Bicycletx Limited |
Combination therapy for use in treating cancer
|
|
WO2025137370A1
(en)
|
2023-12-20 |
2025-06-26 |
Arcus Biosciences, Inc. |
Salt forms of an axl inhibitor
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025155607A1
(en)
|
2024-01-16 |
2025-07-24 |
Genentech, Inc. |
Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025174933A1
(en)
|
2024-02-14 |
2025-08-21 |
Genentech, Inc. |
Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
TW202539744A
(zh)
|
2024-02-27 |
2025-10-16 |
美商必治妥美雅史谷比公司 |
抗ｃｅａｃａｍ５抗體藥物軛合物
|
|
WO2025193759A1
(en)
|
2024-03-12 |
2025-09-18 |
Gilead Sciences, Inc. |
Solid forms of an azolopyrimidine compound
|
|
US20250361297A1
(en)
|
2024-03-12 |
2025-11-27 |
Adaptam Therapeutics, S.L. |
Anti- siglec-15 binding molecules and methods of use
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
WO2025233867A1
(en)
|
2024-05-10 |
2025-11-13 |
Adaptam Therapeutics, S.L. |
Anti-siglec-9 antibodies and uses thereof
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
WO2025254987A1
(en)
|
2024-06-03 |
2025-12-11 |
Alector Llc |
Siglec-9 ecd fusion molecule variants and methods of use thereof
|
|
GB202408360D0
(en)
|
2024-06-11 |
2024-07-24 |
Cancer Research Tech Ltd |
Tumour sensitisation
|
|
WO2026006604A1
(en)
|
2024-06-26 |
2026-01-02 |
Lyell Immunopharma, Inc. |
Feeder cell replacement
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026006759A1
(en)
|
2024-06-28 |
2026-01-02 |
Arcus Biosciences, Inc. |
Pharmaceutical compositions, dosage forms, and methods of making and using same
|